Medical Device: Ophthalmology
MCS closed a $54,000,000 transaction transferring all IP and assets from our client company to NEWCO. Since that time MCS has worked for NEWCO internally as CCO, leading all corporate development, commercialization, and regulatory. MCS efforts secured multiple approvals and certifications and generated a 3X return by taking the the valuation to $170,000,000.
Services Rendered
Corporate Development
Mergers & Acquisitions
Capital Introductions and Value-Based Diligence
Corporate Restructuring for Market Readiness
Product Launch and Market Access
Investor and Public Relations
Milestones Achieved as CCO
FDA PMA Phase II Approval
FDA PMA Phase III IDE Approval
FDA PMA Phase III Clinical Trial Launch
ISO 13485:2016 Certification
Medical Device Single Audit Program (MDSAP) Certification
Health Canada Approved Medical Device License (MDL)
Canadian Market Entry
Seven (7) Approved FDA Supplement Responses
Three (3) Approved Institutional Review Board (IRB) Responses
The medical device is a groundbreaking, patented eyecare technology designed to address prevalent vision impairments through a noninvasive, painless, and rapid procedure (2.5 seconds per eye). Leveraging a unique thulium laser system, The procedures offer immediate improvements in low vision conditions including hyperopia, presbyopia, and age-related macular degeneration (AMD) while providing true multifocality. As an affordable, repeatable alternative to traditional eyewear or invasive surgeries like LASIK, PRK, and IOL, Opti-K minimizes risks, eliminates downtime, and requires no operating room or continued post-operative pharmaceuticals, positioning it for widespread adoption in global markets.

